# The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

> **NCT03084250** · PHASE4 · UNKNOWN · sponsor: **Shanghai Nanhui Nanhua Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Peginterferon Alfa-2A
- **DRUG:** Adefovir, entecavir,tenofovir, either of them

## Key facts

- **NCT ID:** NCT03084250
- **Lead sponsor:** Shanghai Nanhui Nanhua Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-10
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084250, "The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03084250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*